CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer
International Journal of Molecular Sciences · 05.08.2024 · 25 (15) · 8549
DOI: 10.3390/ijms25158549 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.08.2024. Verfasst von Marie C Wesener und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Liver Neoplasms, Adaptor Proteins, Signal Transducing, Transcription Factors, YAP-Signaling Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft SFB/TR 209 "Liver Cancer", Deutsche Forschungsgemeinschaft, Physician-Scientist Program of Heidelberg University, Faculty of Medicine.
Abstract (Originalsprache)
The Hippo pathway transducers yes-associated protein (YAP) and WW-domain containing transcription regulator 1 (WWTR1/TAZ) are key regulators of liver tumorigenesis, promoting tumor formation and progression. Although the first inhibitors are in clinical trials, targeting the relevant upstream regulators of YAP/TAZ activity could prove equally beneficial. To identify regulators of YAP/TAZ activity in hepatocarcinoma (HCC) cells, we carried out a proximity labelling approach (BioID) coupled with mass spectrometry. We verified CRK-like proto-oncogene adaptor protein (CRKL) as a new YAP-exclusive interaction partner. CRKL is highly expressed in HCC patients, and its expression is associated with YAP activity as well as poor survival prognosis. In vitro experiments demonstrated CRKL-dependent cell survival and the loss of YAP binding induced through actin disruption. Moreover, we delineated the activation of the JNK/JUN pathway by CRKL, which promoted YAP transcription. Our data illustrate that CRKL not only promoted YAP activity through its binding but also through the induction of YAP transcription by JNK/JUN activation. This emphasizes the potential use of targeting the JNK/JUN pathway to suppress YAP expression in HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
- CFMP, Core Facility for Mass Spectrometry & Proteomics at the Center for Molecular Biology (ZMBH), Heidelberg University, 69120 Heidelberg, Germany.
- DKFZ, German Cancer Research Center Heidelberg, 69120 Heidelberg, Germany.
ORCID-Profile: Sabine Merker
Förderung
- Deutsche Forschungsgemeinschaft SFB/TR 209 "Liver Cancer"
- Deutsche Forschungsgemeinschaft
- Physician-Scientist Program of Heidelberg University, Faculty of Medicine
- German Ministry of Education and Research (BMBF)
- German Center for Lung Research (DZL)
Zitieren
APA
Wesener, M. C., Weiler, S. M. E., Bissinger, M., Klessinger, T. F., Rose, F., Merker, S., Luzarowski, M., Ruppert, T., Helm, B., Klingmüller, U., Schirmacher, P., & Breuhahn, K. (2024). CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer. International Journal of Molecular Sciences, 25(15), 8549. https://doi.org/10.3390/ijms25158549
Vancouver
Wesener MC, Weiler SME, Bissinger M, Klessinger TF, Rose F, Merker S, et al. CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer. International Journal of Molecular Sciences. 2024;25(15):8549. doi:10.3390/ijms25158549
BibTeX
@article{Wesener2024,
author = {Wesener, Marie C and Weiler, Sofia M E and Bissinger, Michaela and Klessinger, Tobias F and Rose, Fabian and Merker, Sabine and Luzarowski, Marcin and Ruppert, Thomas and Helm, Barbara and Klingmüller, Ursula and Schirmacher, Peter and Breuhahn, Kai},
title = {CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {15},
pages = {8549},
doi = {10.3390/ijms25158549}
}
EUVIMED